Buradasınız

Anasayfa » Content

Asetilsalisilik Asidin Serum Lipidleri Üzerine Olan Etkilerinin Araştırılması

Investigation of Effect of Acetylsalicylic Acid on Serum Lipids

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
The aim of the study was to investigate the effect of 100 and 150 mg/day acetylsalicylic acid (ASA, aspirin) treatment on blood lipids. The study group consisted of 30 healthy volunteers. Of the volunteers, 17 (7F, 10M) received ASA as 100 mg (Group I) and 13 (5F, 8M) received ASA as 150 mg (Group II) daily for a period of two months. Fasting blood samples of the subjects were drawn before and 1 and 2 months after ASA treatment. Serum total cholesterol, high density lipoprotein (HDL) cholesterol and triglyceride levels of the subjects were measured by routine methods. Low-density lipoprotein (LDL) cholesterol levels were calculated by Friedwald formula. Althought total cholesterol, LDL cholesterol and triglyceride levels were slightly decreased and HDL cholesterol levels were slightly increased 2 months after ASA treatment in both groups, the differences between lipid levels were not statistically significant. In conclusion, ASA treatment at 100 and 150 mg daily for a period of 2 months has no significant effect on blood lipid levels and further investigations about ASA treatment for longer time and at higher doses might be useful.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada, 100 ve 150 mg/gün Asetilsalisilik asid (ASA, aspirin) tedavisinin kan lipidleri üzerine etkisini araştırmayı amaçladık. Çalışmaya, toplam 30 sağlıklı gönüllü alındı. İki ay boyunca vakaların 17’si (7K, 10E) günde 100 mg (Grup I) ve 13’ü (5K, 8E) günde 150 mg (Group II) ASA kullandı. Vakaların ASA verilmeden önce ve verildikten 1 ve 2 ay sonra açlık kan örnekleri alındı. Bu kan örneklerinden serum total kolesterol, yüksek dansiteli lipoprotein (HDL) kolesterol, ve trigliserid seviyeleri rutin metodlarla ölçüldü. Düşük dansiteli lipoprotein (LDL) kolesterol seviyeleri Friedwald formülü kullanılarak hesaplandı. Her iki grup da 2 ay boyunca ASA tedavisi sonucu total kolesterol, LDL kolesterol ve trigliserid seviyelerinin biraz azaldığı, HDL kolesterol seviyelerinin ise biraz arttığı ancak bu değişikliklerin istatistiksel açıdan anlamlı olmadığı görüldü. Sonuç olarak günde 2 ay boyunca 100 ve 150 mg ASA tedavisinin kan lipidleri üzerine önemli bir etkisinin olmadığı ve bu konuda daha uzun süreli ve yüksek doz ASA tedavisinin araştırılmasının faydalı olacağı kanaatindeyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-asetilsalisilik-asidin-serum-lipidleri-uzerine-olan-etkilerinin-arastirilmasi.pdf
  • 1
5-8
  • Turkish

REFERENCES

References: 

1. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
2. Hennekens CH. Update on aspirin in the treatment and prevention of
cardiovascular disease. Am J Manag Care 2002; 8: 691-700.
3. Smith JB, Araki H, Lefer AM. Thromboxane A2, prostacyclin and aspirin:
effects on vascular tone and platelet aggregation. Circulation 1980; 62: 19-
25.
4. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships
among dose, effectiveness, and side effects. Chest 1998; 114: 470-88.
5. Wu R, Lamontagne D, de Champlain J. Antioxidative properties
of acetylsalicylic Acid on vascular tissues from normotensive and
spontaneously hypertensive rats. Circulation 2002; 105: 387-92.
6. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in
cardiovascular diseases. J Hypertens 2000; 18: 655-73.
7. Verhoye E, Langlois MR, Rietzchel E, et al. Asklepios Investigators.
Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis
and cardiovascular risk? Clin Chem Lab Med 2009; 47: 128-37.
8. Cyrus T, Yao Y, Tung LX, et al. Stabilization of advanced atherosclerosis in
low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis
2006; 184: 8-14.
9. Kurban S, Mehmetoglu I. Effects of acetylsalicylic acid on serum
paraoxonase activity, Ox-LDL, coenzyme Q(10) and other oxidative stress
markers in healthy volunteers. Clin Biochem. 2009. 10.1016/j.clinbiochem2
009.10.054.
10. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:
115–26.
11. Costanzo A, Moretti F, Burgio VL, et al. Endothelial activation by angiotensin
II through NFkappaB and p38 pathways: Involvement of NFkappaBinducible kinase (NIK), free oxygen radicals, and selective inhibition by
aspirin. J Cell Physiol 2003; 195: 402-10.
12. Tauseef M, Shahid M, Sharma KK, et al. Antioxidative action of aspirin on
endothelial function in hypercholesterolaemic rats. Basic Clin Pharmacol
Toxicol 2008; 103: 314-21.
13. Podhaisky HP, Abate A, Polte T, et al. Aspirin protects endothelial cells from
oxidative stress--possible synergism with vitamin E. FEBS Lett 1997; 417:
349-51.
14. Nobukuni Y, Higashikawa F, Miyagawa K, Eboshida A. Hyperlipidemia:
complex pathophysiology caused by multiple genetic and environmental
factors--in considering the approaches to preventive medicine Nippon
Eiseigaku Zasshi. 2005; 60: 426-441.
15. Gould AL, Davies GM, Alemao E, et al. Cholesterol reduction yields clinical
benefits: meta-analysis including recent trials. Clin Ther 2007; 29: 778-94.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem 1972; 18 :499-502.
17. Kouraklis G, Patapis P, Misiakos E, et al. Effects of acetylsalicylic acid on
experimental atherogenesis induced in rabbits. Int Angiol 2004; 23: 139-
43.
18. Fields M, Lewis CG, Bureau I. Aspirin reduces blood cholesterol in copperdeficient rats: a potential antioxidant agent? Metabolism 2001; 50: 558-61.
19. Prasad K, Lee P. Suppression of oxidative stress as a mechanism of
reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc
Pharmacol Ther 2003; 8: 61-9.
20. Yang XY, Wang L, Zhou N, et al. Antiatherosclerotic mechanism of aspirin:
experiment with rabbits. Zhonghua Yi Xue Za Zhi 2007; 87:3298-301.
21. Guo Y, Wang QZ, Tang BS, et al. Effects of aspirin on atherosclerosis and
the cyclooxygenase-2 expression in atherosclerotic rabbits. Chin Med J
(Engl) 2006; 119:1808-14.
22. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum
concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
Clin Chem 2002; 48: 1454-9.

Thank you for copying data from http://www.arastirmax.com